The FDA approved a targeted therapy entrectinib (Rozlytrek) for either NTRK+ solid tumors* or ROS1+ patients with metastatic non-small cell lung cancer (NSCLC).
News & Views
Find out what’s new at the Lung Cancer Research Foundation. Included below are researcher spotlights, recent developments in lung cancer research — from LCRF grant recipients as well as others in the field, highlights from our signature fundraising events and more.
For media inquiries, please contact Senior Director of Marketing & Communications Emily Krimbel at email@example.com.